Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →
CLEATUS
Get CLEATUS

Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit (U24 Clinical Trial Not Allowed)

Open
PAR-28-057Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The National Cancer Institute is soliciting applications under solicitation PAR-28-057 to establish the Management and Data Coordination Unit as a key scientific component of the Pancreatic Cancer Detection Consortium. This initiative focuses on the early detection of pancreatic ductal adenocarcinoma and the characterization of precursor lesions to identify high-risk patients, aligning with the NCI's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma. The selected unit will be responsible for providing critical infrastructure and collaborative support, including study design, protocol development, statistical analysis, and comprehensive data management. Additionally, the unit will oversee the coordination of biorepository building and provide the necessary organizational and logistics support to ensure the successful operation of the consortium. Applications must be submitted by the deadline of May 26, 2027.

General Info

NCI seeks a Management and Data Coordination Unit for Pancreatic Cancer Detection Consortium.

Agency

National Institutes Of Health → National Cancer Institute

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Place of Performance

Not specified

Set-Aside

NONE

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseSolicitation
Posted

Solicitation

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyNational Institutes Of Health → National Cancer Institute
ContactsNo contacts available
OfficeUSA
Organization / AgencyNational Institutes Of Health → National Cancer Institute
Office AddressUSA
ContactsNo contact information available

Full Description

Show more
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) is soliciting applications for the establishment of the Management and Data Coordination Unit (MDCU), one of the two scientific components of the Pancreatic Cancer Detection Consortium (PCDC). The PCDC will continue to address one of the four research priorities identified in the National Cancer Institute's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma and conduct research on early detection of pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions to identify those patients who are at high risk of progression to cancer. The PCDC-MDCU will provide support towards collaborative efforts such as study design, protocol development, statistical analysis, coordination and data management. Other PCDC-MDCU activities include: coordination and support towards biorepository building; and organizational and logistics support for PCDC activities.

Similar Contracts

Same NAICS industry code

NAICS: 541715
New
SLED
Digital Health Sandbox Environment & Validation ServicesThe Digital Health Sandbox Environment and Validation Services subcontract, issued by the Massachusetts Technology Collaborative, establishes a controlled testing ground for digital health companies working with prime contractors on MassTech and MeHI rural health projects. The initiative provides the necessary infrastructure and clinical settings to test, validate, and pilot healthcare products, with a specific focus on improving the quality and accessibility of healthcare in rural areas. The selected provider is responsible for tracking performance data and delivering comprehensive impact reports to measure the effectiveness of these digital health solutions. Due to the nature of the funding, strict adherence to 2 CFR 200 and Single Audit Act compliance is required. Interested parties must submit responses by December 7, 2026, for work to be performed in Westborough, Massachusetts.
Massachusetts Technology Collaborative

POSTED

about 18 hours ago

DEADLINE

in 26 days
View Details
NAICS: 541715
New
SLED
NOFO 2027-MeHI-02 Rural Digital Health Sandbox Program
Solicitation # BD-27-1367-1367C-1367L-135347
The Massachusetts Technology Collaborative (MassTech) is issuing the Rural Digital Health Sandbox Program (NOFO 2027-MeHI-02) to support digital health companies in testing and validating new products and services within authorized sandbox environments. Funded by the Centers for Medicare & Medicaid Services under the Rural Health Transformation Program, the initiative aims to improve healthcare access, quality, and outcomes within rural communities in Massachusetts. Selected applicants are eligible for grant funding up to $475,000, which is paid directly to the participating sandbox organizations rather than the applicants. Applicants must submit a comprehensive application by December 7, 2026, including a pitch deck, project plan, budget, team bios, a W9, and a signed letter of support from their chosen sandbox. Evaluation is based on commercial viability, the potential to improve rural healthcare, project feasibility, and the ability to scale solutions. A critical requirement for all applicants is a lack of debarment status by both state and federal governments. Sandbox providers receiving these funds must adhere to 2 CFR 200 Uniform Guidance and the Single Audit Act if federal expenditures exceed $1,000,000.
Massachusetts Technology Collaborative

POSTED

about 18 hours ago

DEADLINE

in 26 days
View Details
NAICS: 541715
New
Federal
Replicable, Actionable Projects for Intelligent Transportation Systems (ITS) Deployment, Broad Agency Announcement (RAPID BAA)

POSTED

about 19 hours ago

DEADLINE

N/A
View Details
NAICS: 541715
New
Federal
Oil Spill Response and Mesoscale Testing Subject Matter ExpertThis subcontract opportunity is for an Oil Spill Response and Mesoscale Testing Subject Matter Expert to provide technical analysis for prime contractors on BSEE/MMA projects under the Department of the Interior. The selected expert will focus on analyzing mesoscale oil testing protocols to validate technology readiness and establishing the correlation between mesoscale results and full-scale performance. Key responsibilities include developing technical criteria for TRL gates for oil spill response technologies by leveraging knowledge of the Ohmsett Branch testing facility. Additionally, the contractor will provide critical technical inputs and data analysis to support the development of the TRL Guidebook and the T&E approach document. The solicitation was posted on November 10, 2026, with a response deadline of November 25, 2026.
Bsee Contracting Activity

POSTED

1 day ago

DEADLINE

in 14 days
View Details
NAICS: 541715
New
Federal
Modeling, Simulation, and Tabletop Exercise SupportThis small business set-aside subcontract focuses on providing modeling, simulation, and tabletop exercise support for the Department of Defense at the NSWC Indian Head Division. The scope of work involves the development and execution of simulations for One-Way Attack and Unmanned Systems, utilizing high-performance computing environments to support prime contractors on various weapons systems. The selected provider will be responsible for conducting verification, validation, and accreditation in accordance with DoD 5000.61 standards. Key deliverables include the simulation models themselves, comprehensive VV&A reports, and summaries from tabletop exercises. The opportunity is categorized under NAICS code 541715, with a response deadline set for November 24, 2026.
Nswc Indian Head Division

POSTED

1 day ago

DEADLINE

in 13 days
View Details
NAICS: 541715
New
Federal
Electronic Warfare (EW) & Digital Signal Processing (DSP) DevelopmentThis small business set-aside subcontract focuses on the design and development of analog and digital signal processing systems for prime contractors supporting the Department of Defense at the NSWC Indian Head Division. The scope of work includes preparing workstations for the DSP Laboratory, creating signal processing systems for threat-informed technology improvements, and performing electronic warfare hardening analysis in accordance with MIL-STD-461. The successful contractor will be responsible for delivering functional DSP workstations, specialized signal processing hardware, and detailed threat analysis reports. This effort falls under NAICS code 541715 and is centered in the 20640 zip code area, with a response deadline set for November 24, 2026.
Nswc Indian Head Division

POSTED

1 day ago

DEADLINE

in 13 days
View Details
NAICS: 541715
New
Federal
Acoustic Source Characterization SpecialistThis subcontract opportunity for an Acoustic Source Characterization Specialist supports US Space Force launch noise analysis projects. The selected provider will perform literature reviews and technical characterizations of acoustic signatures for prime contractors, focusing specifically on research regarding sonic booms and launch acoustics for several major vehicles, including Falcon 9, Falcon Heavy, Starship/Super Heavy, Vulcan, and New Glenn. The scope of work involves utilizing signal analysis software and aerospace acoustic databases to develop a comprehensive Acoustic Source Characterization Database. Key deliverables for this effort include the final database and a Phase 1 Report. The work is associated with the Department of Defense and is to be performed in Cape Canaveral, Florida, with a response deadline of December 3, 2026.
FA2521 45 Cons Pk

POSTED

1 day ago

DEADLINE

in 22 days
View Details
NAICS: 541715
New
Federal
Notice of Intent To Award Sole Source WHOI REMUS Support
Solicitation # N6660427RB700
Nuwc Division Newport

POSTED

1 day ago

DEADLINE

in 20 days
View Details
NAICS: 541715
New
Federal
Area of Interest: OSW Cost Assessment and Program Evaluation (CAPE) Modeling and Simulation
Solicitation # HQ003427AOI5
The Department of War Cost Assessment and Program Evaluation CAPE is seeking innovative commercial solutions to replace its legacy modeling and simulation infrastructure with a next-generation computational backbone. The objective is to modernize decision support by implementing a three-layer architecture consisting of a high-performance simulation execution layer, a machine-learned surrogate emulation layer for government-developed models, and an intuitive self-service quantitative analysis layer. This system must dramatically increase throughput, with the capability to execute between 1,200 simulations in 10 hours for light cases and up to 150,000 simulations within two weeks for heavy joint campaign cases. The required solution must operate at Impact Level 6 security accreditation to be accessible from secure spaces at the Pentagon and Mark Center, supporting network throughput between 100 Mbps and 1 Gbps. Technical requirements include compatibility with Python, R, Java, PyTorch, GAMS, and containerized processes. While the commercial provider will manage turnkey platform and infrastructure IT operations, including cybersecurity hardening and patching, the government will retain full operational tenant administration and control over data and user access. This procurement is being conducted as a Commercial Solutions Opening with a Rough Order of Magnitude estimate between 3 million and 22 million dollars. Phase I evaluations focus on the relevance of the solution brief, specifically regarding technical ability, scalability, and security posture. Initial operational capability is anticipated in FY27, with full operational capability expected in FY28. Solution briefs are due by November 16, 2026.
Washington Headquarters Services

POSTED

1 day ago

DEADLINE

in 5 days
View Details
NAICS: 541715
New
Federal
SYSTEM DELTA 84 (SYD 84/MT) MEDIUM EARTH ORBIT MISSILE WARNING / MISSILE TRACKING EPOCH 3 and EPOCH 4, REQUEST FOR INFORMATION (RFI)
Solicitation # FA8810-RFI-26-SYD84-E3E4
Space Systems Command is seeking industry feedback through a Request for Information regarding the production feasibility of Epochs 3 and 4 for the Resilient Missile Warning and Tracking Medium Earth Orbit layer. The government is looking for technical approaches and acquisition strategies to support Full Warfighting Capabilities, specifically focusing on space vehicle delivery, integration, and operations, ground segment command and control facilities, and digital engineering integration. The intended contract structure is a Firm Fixed Price agreement utilizing Other Transaction Authority. The response deadline for this effort is December 2, 2026, with a maximum page count of 50 pages. This opportunity is categorized under NAICS code 541715, and the government strongly encourages participation from small and disadvantaged businesses. Interested vendors must coordinate with government points of contact to receive full documentation, and those seeking classified information must possess at least a Secret facility clearance.
FA8810 Space Sensing Ssc/snk

POSTED

1 day ago

DEADLINE

in 20 days
View Details
NAICS: 541715
New
Federal
SAFE-PLASMA Protocol
Solicitation # HT9427-27-SSN-701
The Defense Health Agency Contracting Activity, acting for the Portfolio Acquisition Executive for Medical Products and the Warfighter Protection and Acute Care Project Management Office, intends to issue a sole-source contract modification to Westat Inc. This action is designed to update the SAFE-PLASMA Protocol clinical trial design to align with FDA recommendations and ensure the trial is conducted in accordance with Good Clinical Practices (GCP). The primary objective is to evaluate the safety of EZPLAZ and conventional plasma products in adult patients to meet the necessary requirements for EZPLAZ approval. The scope of work includes the implementation of a specific protocol and Statistical Analysis Plan. This effort is categorized under NAICS code 541715 and is managed by the Defense Health Agency with performance located in Maryland. As this is currently a Sources Sought Notice for market research and planning purposes, the agency is seeking capability statements from interested sources, including technical data and rough order of magnitude estimates, to be submitted via email by November 16, 2026.
Defense Health Agency

POSTED

1 day ago

DEADLINE

in 5 days
View Details
NAICS: 541715
New
Federal
NIMHD Division of Intramural Research Population Health and Clinical Research — Small Business Sources Sought
Solicitation # 75N94027R00005
The National Institute on Minority Health and Health Disparities (NIMHD) is conducting market research via a Small Business Sources Sought notice to identify qualified small businesses capable of providing research and development social and behavioral sciences services. The objective is to support the NIMHD Division of Intramural Research in conducting population health and clinical research aimed at understanding and reducing health disparities in the United States. The government anticipates awarding an Indefinite Delivery Indefinite Quantity (IDIQ) contract around September 2027. The scope of work involves designing and overseeing clinical and technical investigations using methods such as epidemiological studies, clinical trials, and qualitative research, while managing the recruitment of participants and the coordination of multiple research sites. The required services include comprehensive project management, regulatory compliance assurance, and the provision of qualified personnel, including medical, nursing, and neuropsychologic staff. Contractors must ensure adherence to Good Clinical Practices (GCP), Good Clinical Laboratory Practices (GCLP), and FISMA security standards, while managing FDA-compliant reporting for adverse experiences. This effort is categorized under NAICS code 541715, with a small business size standard of 1,000 employees or less. Interested small businesses must submit an electronic capability statement of 20 pages or less to the Contracting Officer and Contract Specialist by November 25, 2026, detailing their business status, UEI, and CAGE code.
National Institutes Of Health Olao

POSTED

1 day ago

DEADLINE

in 14 days
View Details

More opportunities from National Institutes Of Health → National Cancer Institute

Same awarding agency

NAICS: 541715
Grant
NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed)
Solicitation # PAR-28-063
The National Cancer Institute is offering the Research Specialist Award (R50) under solicitation PAR-28-063 to support exceptional clinician scientists involved in NCI-funded clinical trials research. This award aims to create stable career paths for professionals who provide leadership in developing national clinical trials, implementing these trials within their own institutions, and serving on scientific review or monitoring committees. The program is specifically designed for those who wish to maintain a high level of influence and service within NCI clinical trials networks without serving as principal investigators on research project grants. By providing dedicated salary support and increased professional autonomy, the award ensures that these vital clinician scientists are not solely dependent on external funding or grants held by other individuals. This initiative is intended to sustain the overall NCI clinical trials enterprise by securing the continuity of experienced research careers. Applications for this federal opportunity are open until February 21, 2029.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

9 days ago

DEADLINE

in over 2 years
View Details
NAICS: 541714
Grant
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
Solicitation # PAR-28-042
The National Cancer Institute, under the National Institutes of Health, has issued solicitation PAR-28-042 to provide funding for the analytical and clinical validation of biomarkers and assays related to cancer. This initiative focuses on molecular, cellular, and imaging markers used for detection, diagnosis, prognosis, treatment response, prevention, and toxicity monitoring. The goal is to support laboratory optimization and validation for assays using human samples that address specific clinical needs and intended uses. Eligible projects may utilize either a standalone UH3 mechanism or a phased UH2/UH3 approach, though clinical trials are explicitly not allowed. The solicitation was posted on November 3, 2026, with a response deadline set for November 17, 2029.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

9 days ago

DEADLINE

in about 3 years
View Details
NAICS: 923120
Grant
Notice of Change: Grants Administration Information added for NCI's Participation on PA-27-036, NIH Research Education Program - Research Experiences (Parent R25 - Clinical Trial Not Allowed)
Solicitation # NOT-CA-26-019
This Notice of Change, identified by solicitation number NOT-CA-26-019, updates the NIH Research Education Program - Research Experiences (Parent R25 - Clinical Trial Not Allowed) under PA-27-036. The primary purpose of this amendment is to incorporate specific Grants Administration Information regarding the National Cancer Institute's participation in the program. The update specifically modifies Section VII, Agency Contacts, to include the Office of Grants Administration for the National Cancer Institute as a financial and grants management contact. No other changes have been made to the original PA-27-036 guidelines. Interested parties can coordinate with the Center for Cancer Training or the Office of Grants Administration for further inquiries.
Administration of Public Health Programs

POSTED

22 days ago

DEADLINE

N/A
View Details
NAICS: 621991
Grant
Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)
Solicitation # RFA-CA-28-004
The National Cancer Institute is issuing a limited competition Notice of Funding Opportunity, solicitation RFA-CA-28-004, to support the continuation of two critical biospecimen banking resources. These resources include the National Clinical Trials Network Biobanks, which support the NCTN and the Community Oncology Research Program, and the Early-Phase and Experimental Clinical Trials Biospecimen Bank, which supports the ETCTN and other early-phase experimental trials. The primary objective is to maintain national infrastructure for the collection, processing, storage, and distribution of high-quality, clinically annotated human biospecimens to enable translational cancer research, biomarker development, and the study of drug response and resistance. Eligible organizations must submit applications by February 12, 2027, to be considered for funding. All submissions will undergo a standard NIH peer-review process, and only meritorious applications will be selected. These banks are essential for linking biospecimens to clinical outcome data from large multi-site trials and supporting the development of novel cancer therapies through pharmacokinetic and pharmacodynamic analyses.
Blood and Organ Banks

POSTED

28 days ago

DEADLINE

in 3 months
View Details
NAICS: 541714
Grant
Early-Onset Cancers: Investigating Etiology, Mechanisms, and Early Detection Strategies (RP1 Clinical Trials Optional)
Solicitation # PAR-28-014
The National Cancer Institute, under the National Institutes of Health, is soliciting applications for solicitation PAR-28-014 to investigate the causes and biological mechanisms of sporadic non-hereditary early-onset cancers in adults aged 18 to 49. The primary goal of this initiative is to understand the rising incidence of these cancers to improve prevention and control strategies. Research should specifically target environmental or lifestyle drivers across various demographics, the biological host responses involved, or the development of more effective methods for identifying high-risk individuals. This funding opportunity supports both standard research projects and exploratory or developmental studies through a grant award instrument, with clinical trials being optional. Interested parties must submit their applications by the deadline of October 12, 2029.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

29 days ago

DEADLINE

in almost 3 years
View Details
NAICS: 541714
Grant
Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required)
Solicitation # PAR-28-022
The National Cancer Institute, potentially in collaboration with the National Institute of Dental and Craniofacial Research, is soliciting applications for P50 Research Center Grants for Specialized Programs of Research Excellence. This program supports investigator-initiated translational research focused on the prevention, early detection, diagnosis, and treatment of organ-specific cancers or closely related cancer groups. Eligible research must be grounded in human biology using genetic, molecular, biochemical, structural, or cellular experimental approaches and must achieve a translational human endpoint within the grant period. Under solicitation number PAR-28-022, this opportunity covers the years 2027, 2028, and 2029 and requires the inclusion of clinical trials. The notice was posted on October 14, 2026, with a final response deadline of September 26, 2029. This initiative serves as a re-issuance of PAR-23-284 to continue funding state-of-the-art research aimed at improving clinical outcomes for cancer patients.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

29 days ago

DEADLINE

in almost 3 years
View Details
NAICS: 541715
Grant
Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed)
Solicitation # RFA-CA-28-013
The National Cancer Institute, under the National Institutes of Health, is seeking meritorious proposals for the Carcinogen Hazard Assessment Monographs Program (CHAMP) Initiative. This solicitation, identified as RFA-CA-28-013, aims to fund projects that critically and systematically evaluate scientific evidence regarding carcinogenic hazards to humans to better inform cancer research, control, and prevention efforts. Interested applicants must submit their proposals by the response deadline of February 10, 2027. This opportunity is categorized as an R01 grant, and it is explicitly noted that clinical trials are not allowed under this specific funding program.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

about 1 month ago

DEADLINE

in 3 months
View Details
NAICS: 541714
Grant
Notice of Change in Application Due Date for RFA-CA-27-005 "Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)"
Solicitation # NOT-CA-26-020
This notice issued by the National Cancer Institute of the National Institutes of Health serves to amend the application timeline for the Glioblastoma Therapeutics Network clinical trial solicitation, RFA-CA-27-005. The primary modification is the addition of a second application due date on January 11, 2027, for new, renewal, resubmission, and revision applications. Under this new cycle, the scientific merit review is scheduled for June 2027, followed by an advisory council review in August 2027, with an earliest start date of December 2027. The expiration date for this specific window is January 12, 2027. All other terms and conditions of the original notice of funding opportunity remain unchanged.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

about 1 month ago

DEADLINE

N/A
View Details
NAICS: 541714
Grant
Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)
Solicitation # PAR-28-056
The National Cancer Institute is soliciting applications for Research Units as part of the Pancreatic Cancer Detection Consortium to advance the early detection of pancreatic ductal adenocarcinoma and the characterization of precursor lesions. These multi-disciplinary teams will focus on developing and testing molecular and imaging biomarkers to identify high-risk patients and those with lesions likely to progress to cancer. Key research activities include the use of machine learning for biomarker discovery, conducting validation studies, and collecting longitudinal biospecimens for a centralized biorepository. Under solicitation PAR-28-056, the selected Research Units are required to engage in collaborative efforts, sharing data and biospecimens across the consortium. The initiative aligns with the NCI's scientific framework for pancreatic cancer by prioritizing the identification of patients who could benefit from early intervention based on genetic factors, family history, or existing precursor lesions. Applications for this federal opportunity are due by November 6, 2029.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

about 2 months ago

DEADLINE

in almost 3 years
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS